Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis (Healing):** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. Doses of 20 mg orally may be sufficient for some patients.
* **Pathological Hypersecretory Conditions:** 40 mg orally or intravenously twice daily initially. Doses may be increased as clinically warranted. Doses up to 240 mg intravenously daily have been administered.
## Pediatric Dosing
* **12 to 17 years:**
* **Healing of Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **5 to 11 years:**
* **Healing of Erosive Esophagitis:** 20 mg orally once daily for up to 8 weeks. May increase to 40 mg orally once daily if needed.
* **Infants < 5 years:** Dosing is not well-established for this age group; consult specific pediatric guidelines or literature.
## Dose Adjustments
No dose adjustment is typically necessary for hepatic impairment, although caution may be advised with severe impairment. No dose adjustment is needed for renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Use of rilpivirine-containing products.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs may be associated with an increased risk of:
* Fractures (hip, wrist, spine)
* Clostridium difficile infection
* Vitamin B12 deficiency
* Hypomagnesemia
## Key Drug Interactions
* **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Consider alternatives or monitor for efficacy.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Drugs Dependent on Gastric pH:** Absorption of drugs such as ketoconazole, itraconazole, and certain HIV protease inhibitors may be decreased.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19.
## Monitoring
* Monitor for improvement in GERD symptoms.
* Monitor electrolytes (especially magnesium) with prolonged therapy or concurrent diuretic use.
* Monitor for signs and symptoms of C. difficile infection.
* Monitor for signs of vitamin B12 deficiency with long-term use.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* For IV administration, reconstitute with 5 mL sterile water for injection and then further dilute in 50 mL of 0.9% Sodium Chloride injection or 5% Dextrose injection.
* Consider discontinuing PPIs if possible when initiating clopidogrel, or closely monitor for cardiovascular outcomes.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date details.
